FDL 169

Drug Profile

FDL 169

Alternative Names: FDL-169

Latest Information Update: 08 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Flatley Discovery Lab
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cystic fibrosis

Most Recent Events

  • 03 Apr 2017 Flatley Discovery Lab plans a phase I trial for Cystic fibrosis (NCT03093714)
  • 08 Nov 2016 Flatley Discovery Lab completes a phase I/II trial in Cystic fibrosis in United Kingdom (NCT02767297)
  • 01 Apr 2016 Phase-I/II clinical trials in Cystic fibrosis in United Kingdom (PO, Tablet and Capsule) (NCT02767297)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top